A phase 2 randomized study of comparison between comparing uliledlimab plus toripalimab to pembrolizumab alone and toripalimab alone in newly diagnosed patients with advanced NSCLC

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Toripalimab (Primary) ; Uliledlimab (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use

14 Nov 2024 According to an I-MAB Biopharma media release, the Company is on track to dose the first patient in the randomized Phase 2 study in patients with first-line mNSCLC testing multiple doses of uliledlimab in combination with pembrolizumab plus chemotherapy versus standard of care in 1H 2025.
10 Sep 2024 According to an I-MAB Biopharma media release, Phase 2 study of uliledlimab in combination with pembrolizumab plus chemotherapy expected to begin in 1H 2025.
28 Aug 2024 According to an I-MAB Biopharma media release, patient enrollment is expected to begin in the 1H 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com